STOCK TITAN

Personalis, Inc. - $PSNL STOCK NEWS

Welcome to our dedicated page for Personalis news (Ticker: $PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Personalis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Personalis's position in the market.

Rhea-AI Summary
Personalis to present data on its NeXT Personal® assay at the 2023 ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary
Personalis appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance and achieves ISO 13485:2016 certification
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
management
-
Rhea-AI Summary
Personalis, Inc. to present at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
Rhea-AI Summary
Personalis grants stock options and restricted stock units to new employees under its 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
none
-
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) reported a 8% decrease in total company revenue for the second quarter of 2023, with a net loss of $24.0 million. The company also announced a collaboration with National Cancer Center Hospital East and Ono Pharmaceutical Co. Ltd for biomarker analysis, renewal options under the VA MVP contract, and a second patent infringement lawsuit against Foresight Diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
-
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) to Participate in Upcoming Investor Conferences for Precision Oncology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences
Rhea-AI Summary
Personalis, Inc. (Nasdaq: PSNL) to Release Q2 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.93%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
none
Personalis, Inc.

Nasdaq:PSNL

PSNL Rankings

PSNL Stock Data

75.83M
41.21M
0.82%
58.15%
2.14%
Medical Laboratories
Health Care and Social Assistance
Link
United States of America
FREMONT

About PSNL

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.